{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:40:54Z","timestamp":1792604454340,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"DOI":"10.1007\/s11606-026-10945-y","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:17:49Z","timestamp":1792603069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discriminatory Practice in Opioid Use Disorder: In a Post-X-Waiver Era, Barriers to Buprenorphine Persist"],"prefix":"10.1007","author":[{"given":"Hannah","family":"Freibert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Lofwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"South","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"10945_CR1","unstructured":"VA\/DoD Clinical Practice Guideline. Use of Opioids in the Management of Chronic Pain Work Group. Washington, DC: U.S. Government Printing Office. 2022."},{"key":"10945_CR2","doi-asserted-by":"publisher","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.\u00a0BMJ. 2017;357:j1550. Published 2017 Apr 26. https:\/\/doi.org\/10.1136\/bmj.j1550.","DOI":"10.1136\/bmj.j1550"},{"key":"10945_CR3","doi-asserted-by":"publisher","unstructured":"Maremmani I, Dematteis M, Gorzelanczyk EJ, Mugelli A, Walcher S, Torrens M. Long-acting buprenorphine formulations as a new strategy for the treatment of opioid use disorder. J Clin Med. 2023;12(17):5575. Published 2023 Aug 26. https:\/\/doi.org\/10.3390\/jcm12175575.","DOI":"10.3390\/jcm12175575"},{"key":"10945_CR4","doi-asserted-by":"publisher","unstructured":"Andorn AC, Haight BR, Shinde S, et al. Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis. J Clin Psychopharmacol. 2020;40(3):231\u2013239. https:\/\/doi.org\/10.1097\/JCP.0000000000001195.","DOI":"10.1097\/JCP.0000000000001195"},{"issue":"5","key":"10945_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.5055\/jom.2018.0526","volume":"15","author":"MM Sweeney","year":"2019","unstructured":"Sweeney MM, Antoine DG, Nanda L, et al. Increases in body mass index and cardiovascular risk factors during methadone maintenance treatment. J Opioid Manag. 2019;15(5):367\u2013374. https:\/\/doi.org\/10.5055\/jom.2018.0526.","journal-title":"J Opioid Manag."},{"issue":"5","key":"10945_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/00952990.2023.2207720","volume":"49","author":"MM Carr","year":"2023","unstructured":"Carr MM, Lou R, Macdonald-Gagnon G, et al. Weight change among patients engaged in medication treatment for opioid use disorder: a scoping review. Am J Drug Alcohol Abuse. 2023;49(5):551\u2013565. https:\/\/doi.org\/10.1080\/00952990.2023.2207720.","journal-title":"Am J Drug Alcohol Abuse."},{"issue":"12","key":"10945_CR7","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2165\/11635500-000000000-00000","volume":"72","author":"M Bosilkovska","year":"2012","unstructured":"Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs. 2012;72(12):1645\u20131669. https:\/\/doi.org\/10.2165\/11635500-000000000-00000.","journal-title":"Drugs."},{"key":"10945_CR8","doi-asserted-by":"publisher","unstructured":"Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309\u2013318. https:\/\/doi.org\/10.1016\/S0140-6736(17)32812-X.","DOI":"10.1016\/S0140-6736(17)32812-X"},{"key":"10945_CR9","doi-asserted-by":"publisher","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022;71(3):1\u201395. Published 2022 Nov 4. https:\/\/doi.org\/10.15585\/mmwr.rr7103a1.","DOI":"10.15585\/mmwr.rr7103a1"},{"issue":"10","key":"10945_CR10","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/jhm.13176","volume":"18","author":"LA Haber","year":"2023","unstructured":"Haber LA, Nguyen OK, Taub J, Martin M. Policy in clinical practice: elimination of the buprenorphine \u201cX-waiver\u201d. J Hosp Med. 2023;18(10):931\u2013933. https:\/\/doi.org\/10.1002\/jhm.13176.","journal-title":"J Hosp Med."},{"issue":"16","key":"10945_CR11","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1056\/NEJMc2312906","volume":"390","author":"KP Chua","year":"2024","unstructured":"Chua KP, Bicket MC, Bohnert ASB, Conti RM, Lagisetty P, Nguyen TD. Buprenorphine dispensing after elimination of the waiver requirement. N Engl J Med. 2024;390(16):1530\u20131532. https:\/\/doi.org\/10.1056\/NEJMc2312906.","journal-title":"N Engl J Med."},{"key":"10945_CR12","unstructured":"Centers for Disease Control and Prevention. Pharmacy dispensed opioid, buprenorphine, and naloxone. https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/us-dispensing-rate-maps.html. Accessed 24 Jan 2025."},{"issue":"4","key":"10945_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5055\/jom.0827","volume":"20","author":"MP Gannon","year":"2024","unstructured":"Gannon MP, Tello M, Wakeman S, Charles JP, Lipsitz S, Samal L. Attitudinal barriers to buprenorphine prescription and former waiver training. J Opioid Manag. 2024;20(4):339\u2013346. https:\/\/doi.org\/10.5055\/jom.0827.","journal-title":"J Opioid Manag."},{"issue":"14","key":"10945_CR14","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56(14):2181\u20132201. https:\/\/doi.org\/10.1080\/10826084.2021.1975749.","journal-title":"Subst Use Misuse."},{"key":"10945_CR15","doi-asserted-by":"publisher","unstructured":"Bharadwaj R, Mangino AA, Ruf K, et al.\u00a0Hospitalist buprenorphine prescribing before and after x-waiver removal at an academic center.\u00a0J Gen Intern Med.\u00a02026. https:\/\/doi.org\/10.1007\/s11606-026-10296-8.","DOI":"10.1007\/s11606-026-10296-8"},{"key":"10945_CR16","doi-asserted-by":"publisher","unstructured":"Cohen SM, Joab R, Bolles KM, Friedman S, Kimmel SD. Ending medical complicity with skilled-nursing facility discrimination against people with opioid use disorder. Ann Intern Med. 2023;176(3):410-412. https:\/\/doi.org\/10.7326\/M22-3049.","DOI":"10.7326\/M22-3049"},{"key":"10945_CR17","doi-asserted-by":"publisher","unstructured":"Moyo P, Nishar S, Merrick C, et al. Perspectives on admissions and care for residents with opioid use disorder in skilled nursing facilities. JAMA Netw Open. 2024;7(2):e2354746. Published 5 Feb 2024. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.5474.","DOI":"10.1001\/jamanetworkopen.2023.5474"},{"key":"10945_CR18","doi-asserted-by":"publisher","unstructured":"Marfil-Garza BA, Belaunzar\u00e1n-Zamudio PF, Gulias-Herrero A, et al. Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico [published correction appears in PLoS One. 2018 Dec 21;13(12):e0209944]. PLoS One. 2018;13(11):e0207203. Published 8 Nov 2018. https:\/\/doi.org\/10.1371\/journal.pone.0207203.","DOI":"10.1371\/journal.pone.0207203"},{"key":"10945_CR19","doi-asserted-by":"publisher","unstructured":"Barba R, Marco J, Canora J, et al. Prolonged length of stay in hospitalized internal medicine patients. Eur J Intern Med. 2015;26(10):772-775. https:\/\/doi.org\/10.1016\/j.ejim.2015.10.011.","DOI":"10.1016\/j.ejim.2015.10.011"},{"key":"10945_CR20","unstructured":"Legal Action Center. Cases Involving discrimination based on treatment with medication for opioid use disorder (MOUD). 2025. https:\/\/www.lac.org\/assets\/files\/Cases-involving-denial-of-access-to-MOUD.pdf. Accessed 20 June 2026."},{"key":"10945_CR21","unstructured":"Temple University Center for Public Health Law Research, Vital Strategies. Buprenorphine prescribing requirements and limitations. LawAtlas.org. Published 26 Mar 2025. https:\/\/lawatlas.org\/datasets\/buprenorphine-prescribing-requirements-and-limitations. Accessed 21 June 2026."},{"key":"10945_CR22","doi-asserted-by":"publisher","unstructured":"South AM, Fanucchi L, Lofwall M. Treating opioid use disorder in patients who are incarcerated: quandaries of a hospitalist. JAMA. 2023;329(20):1738-1739. https:\/\/doi.org\/10.1001\/jama.2023.5904.","DOI":"10.1001\/jama.2023.5904"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10945-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:17:51Z","timestamp":1792603071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10945-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":22,"alternative-id":["10945"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10945-y","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient gave written permission for this publication.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate\/Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MRL has been a scientific consultant in the last three years for medications and devices in development (unrelated to this paper) for Berkshire Biomedical, Braeburn Pharmaceuticals, and Sophrosyne. The other authors report no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}